Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Ryuichi Ebisawa"'
Autor:
Hajime Suzuki, Mitsuyoshi Nakamura, Junichiro Sawa, Ayaka Sano, Takanori Tsuda, Ryuichi Ebisawa, Jotaro Shinagawa, Xinbin Qiu, Yayoi Kondo, Nobuyuki Shiga, Koji Ando, Akihiro Maruhashi, Naomi Shimada, Hiromi Sasamoto
Publikováno v:
Annals of Oncology. 30:vi94-vi95
Background Clinical Research Organizations (CROs) have been required to ensure delivery of expertise and high-quality services and promptly conduct a clinical trial. Shortening the duration of a clinical trial is considered to have a great impact on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d18e1f625d9399180721b0789c555e82
https://doi.org/10.1093/annonc/mdz338.021
https://doi.org/10.1093/annonc/mdz338.021
Autor:
Ryuichi Ebisawa, Nobuyuki Yamamoto, Akira Inoue, Katsuyuki Kiura, Yoko Seki, Kunihiko Koboyashi, Takeshi Horai, Toyoaki Hida, Kazuto Nishio, Koji Takeda, Nobuyuki Katakami, Shinji Atagi, Yukito Ichinose, Koichi Goto, Mehdi Shahidi
Publikováno v:
Journal of Clinical Oncology. 31:3335-3341
Purpose New molecular targeted agents are needed for patients with non–small-cell lung cancer (NSCLC) who progress while receiving erlotinib, gefitinib, or both. Afatinib, an oral irreversible ErbB family blocker, has preclinical activity in epider
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b85d9a9bf4ec1eb64d8acee7de1b7bf6
https://doi.org/10.1200/jco.2012.45.0981
https://doi.org/10.1200/jco.2012.45.0981
Autor:
Takashi KOSHIMIZU, Hideki SUGANAMI, Tatsuya INOHARA, So SAOTOME, Takao TAKASE, Ichiro NAOI, Kenshi HAYASHIDA, Satoshi YOSHIDA, Tsutomu YAJIMA, Hiroki AKIYAMA, Masaharu KATO, Naoko SHIMOFURUTANI, Megumi TOKI, Atsushi HAGINO, Nobutaka YAGI, Tadaaki YAMADA, Ryuichi EBISAWA, Takayuki IIMORI, Takeshi KANOO, Hiroya HASHIMOTO, Nobuya HAYASHI
Publikováno v:
Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 40:129S-130S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e7fb0d9b62a92367dd14a83725031b51
https://doi.org/10.3999/jscpt.40.129s
https://doi.org/10.3999/jscpt.40.129s
Autor:
Nobuyuki Katakami, Shinji Atagi, Koichi Goto, Toyoaki Hida, Takeshi Horai, Akira Inoue, Yukito Ichinose, Kunihiko Koboyashi, Koji Takeda, Katsuyuki Kiura, Kazuto Nishio, Yoko Seki, Ryuichi Ebisawa, Mehdi Shahidi, Nobuyuki Yamamoto
Publikováno v:
Journal of Clinical Oncology; 9/20/2013, Vol. 31 Issue 27, p3335-3341, 8p
Autor:
Katakami N; Nobuyuki Katakami, Kobe City Medical Center General Hospital, Kobe; Shinji Atagi, National Hospital Organization Kinki-Chuo Chest Medical Center; Koji Takeda, Osaka City General Hospital; Kazuto Nishio, Kinki University, Osaka; Koichi Goto, National Cancer Center Hospital East, Chiba; Toyoaki Hida, Aichi Cancer Center Hospital, Nagoya; Takeshi Horai, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo; Akira Inoue, Tohoku University Hospital, Sendai; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Kunihiko Koboyashi, Saitama International Medical Center, Saitama; Katsuyuki Kiura, Okayama University, Okayama; Yoko Seki and Ryuichi Ebisawa, Nippon Boehringer Ingelheim; Nobuyuki Yamamoto, Shizuoka Cancer Center, Shizuoka, Japan; and Mehdi Shahidi, Boehringer Ingelheim, Bracknell, United Kingdom., Atagi S, Goto K, Hida T, Horai T, Inoue A, Ichinose Y, Koboyashi K, Takeda K, Kiura K, Nishio K, Seki Y, Ebisawa R, Shahidi M, Yamamoto N
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2013 Sep 20; Vol. 31 (27), pp. 3335-41. Date of Electronic Publication: 2013 Jul 01.